(Q46530327)

22 December 2017

title

Assays for prostate cancer : changing the screening paradigm? (English)

1 reference

22 December 2017

author

Felix Chun

5

1 reference

22 December 2017

Shahrokh Shariat

4

object named as

Shahrokh Shariat

1 reference

22 December 2017

author name string

Jens Hansen

1

1 reference

22 December 2017

Michael Rink

2

1 reference

22 December 2017

Markus Graefen

3

1 reference

22 December 2017

publication date

1 February 2013

1 reference

22 December 2017

Molecular Diagnosis and Therapy

published in

1 reference

22 December 2017

volume

17

1 reference

22 December 2017

issue

1

1 reference

22 December 2017

page(s)

1-8

1 reference

22 December 2017

https://scigraph.springernature.com/pub.10.1007/s40291-013-0014-y

exact match

0 references

cites work

Cancer statistics, 2012

1 reference

https://api.crossref.org/works/10.1007%2FS40291-013-0014-Y

Cancer survival among US whites and minorities: a SEER (Surveillance, Epidemiology, and End Results) Program population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-013-0014-Y

Declining death rates reflect progress against cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-013-0014-Y

Screening and prostate-cancer mortality in a randomized European study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-013-0014-Y

Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-013-0014-Y

Molecular diagnosis of prostate cancer: PCA3 and TMPRSS2:ERG gene fusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-013-0014-Y

Tumor markers in prostate cancer I: blood-based markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-013-0014-Y

Tumour markers in prostate cancer III: biomarkers in urine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-013-0014-Y

Contemporary role of prostate cancer antigen 3 in the management of prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-013-0014-Y

Method for evaluating prediction models that apply the results of randomized trials to individual patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-013-0014-Y

A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-013-0014-Y

Systematic review of statistical methods used in molecular marker studies in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-013-0014-Y

Challenges of cancer biomarker profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-013-0014-Y

Role of nomograms for prostate cancer in 2007.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-013-0014-Y

New circulating biomarkers for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-013-0014-Y

Development of common data elements: the experience of and recommendations from the early detection research network

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-013-0014-Y

Prostate-specific antigen and prostate cancer: prediction, detection and monitoring.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-013-0014-Y

Early detection of prostate cancer in 2007. Part 1: PSA and PSA kinetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-013-0014-Y

Blood biomarkers for prostate cancer detection and prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-013-0014-Y

Inventory of prostate cancer predictive tools

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-013-0014-Y

Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-013-0014-Y

Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-013-0014-Y

Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-013-0014-Y

Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-013-0014-Y

Prevalence and clinical significance of prostate cancer among 12,682 men with normal digital rectal examination, low PSA levels (< or =4 ng/ml) and percent free PSA cutoff values of 15 and 20%.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-013-0014-Y

Free prostate-specific antigen in serum is becoming more complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-013-0014-Y

A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-013-0014-Y

Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-013-0014-Y

The new human tissue kallikrein gene family: structure, function, and association to disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-013-0014-Y

Serum human glandular kallikrein-2 protease levels predict the presence of prostate cancer among men with elevated prostate-specific antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-013-0014-Y

Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-013-0014-Y

Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-013-0014-Y

Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-013-0014-Y

Prognostic value of combined "triple"-reverse transcription-PCR analysis for prostate-specific antigen, human kallikrein 2, and prostate-specific membrane antigen mRNA in peripheral blood and lymph nodes of prostate cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-013-0014-Y

Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-013-0014-Y

DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-013-0014-Y

Molecular PCA3 diagnostics on prostatic fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-013-0014-Y

PCA3: a molecular urine assay for predicting prostate biopsy outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-013-0014-Y

APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-013-0014-Y

Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-013-0014-Y

PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-013-0014-Y

Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-013-0014-Y

External validation of urinary PCA3-based nomograms to individually predict prostate biopsy outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-013-0014-Y

Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-013-0014-Y

PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-013-0014-Y

The relationship between Prostate CAncer gene 3 (PCA3) and prostate cancer significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-013-0014-Y

PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-013-0014-Y

Predictive value of PCA3 in urinary sediments in determining clinico-pathological characteristics of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-013-0014-Y

Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-013-0014-Y

Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-013-0014-Y

Evaluation of the ETS-related gene mRNA in urine for the detection of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-013-0014-Y

TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-013-0014-Y

Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-013-0014-Y

TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-013-0014-Y

Multicenter evaluation of an investigational prostate cancer methylation assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-013-0014-Y

Frequent 14-3-3 sigma promoter methylation in benign and malignant prostate lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-013-0014-Y

Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-013-0014-Y

Annexin A3 in urine: a highly specific noninvasive marker for prostate cancer early detection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-013-0014-Y

Clinical evaluation of the PCA3 assay in guiding initial biopsy decisions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-013-0014-Y

New blood-based biomarkers for the diagnosis, staging and prognosis of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-013-0014-Y

A panel of kallikrein markers can predict outcome of prostate biopsy following clinical work-up: an independent validation study from the European Randomized Study of Prostate Cancer screening, France

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-013-0014-Y

A four-kallikrein panel for the prediction of repeat prostate biopsy: data from the European Randomized Study of Prostate Cancer screening in Rotterdam, Netherlands.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-013-0014-Y

A multiplex model of combining gene-based, protein-based, and metabolite-based with positive and negative markers in urine for the early diagnosis of prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-013-0014-Y

A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-013-0014-Y

Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-013-0014-Y

A [-2]proPSA-based artificial neural network significantly improves differentiation between prostate cancer and benign prostatic diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-013-0014-Y

Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-013-0014-Y

Free PSA isoforms and intact and cleaved forms of urokinase plasminogen activator receptor in serum improve selection of patients for prostate cancer biopsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-013-0014-Y

TMPRSS2-ERG Fusion Prostate Cancer: An Early Molecular Event Associated With Invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-013-0014-Y

Diversity of TMPRSS2-ERG fusion transcripts in the human prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-013-0014-Y

Improved prediction of disease relapse after radical prostatectomy through a panel of preoperative blood-based biomarkers

21 January 2018

1 reference

12 December 2020

Percent free prostate specific antigen is not an independent predictor of organ confinement or prostate specific antigen recurrence in unscreened patients with localized prostate cancer treated with radical prostatectomy

1 reference

12 December 2020

New cancer biomarkers deriving from NCI early detection research.

1 reference

12 December 2020

Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer

1 reference

12 December 2020

In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL

1 reference

12 December 2020

Overdiagnosis Due to Prostate-Specific Antigen Screening: Lessons From U.S. Prostate Cancer Incidence Trends

1 reference

12 December 2020

Judging New Markers by Their Ability to Improve Predictive Accuracy

1 reference

12 December 2020

Perspectives on prostate cancer biomarkers

1 reference

12 December 2020

Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer

1 reference

12 December 2020

Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay

1 reference

12 December 2020

A meta-analysis of the performance characteristics of the free prostate-specific antigen test

1 reference

12 December 2020

Improved prostate cancer-specific survival and other disease parameters: impact of prostate-specific antigen testing

1 reference

12 December 2020

Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum

1 reference

12 December 2020

Pre-operative percent free PSA predicts clinical outcomes in patients treated with radical prostatectomy with total PSA levels below 10 ng/ml

1 reference

12 December 2020

A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer.

1 reference

12 December 2020

The New Human Tissue Kallikrein Gene Family: Structure, Function, and Association to Disease1

1 reference

12 December 2020

Significance of different molecular forms of serum PSA. The free, noncomplexed form of PSA versus that complexed to alpha 1-antichymotrypsin

1 reference

12 December 2020

The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma

1 reference

12 December 2020

Prostate cancer detection in men with a 'normal' total prostate-specific antigen (PSA) level using percentage free PSA: a prospective screening study

1 reference

12 December 2020

Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach

1 reference

12 December 2020

10.1007/S40291-013-0014-Y

Identifiers

DOI

1 reference

22 December 2017

1 reference

22 December 2017